^
Association details:
| Biomarker: | NFE2L2 mutation + CTNNB1 mutation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nrf2 and ß-catenin coactivation in hepatocellular cancer: Biological and therapeutic implications
Published date:
10/02/2020
Excerpt:
NFE2L2-CTNNB1 HCC mice were treated with mTOR inhibitor everolimus (5mg/kg diet ad libitum), which led to >50% decrease in tumor burden...Co-expression of mutant-NFE2L2 and mutant-CTNNB1 led to clinically relevant HCC development in mice, which responded to mTOR inhibitors.
DOI:
10.1002/hep.31730
